There is no specific news today explaining the decline in Sangamo Therapeutics, Inc.'s stock price. However, the recent developments regarding the company's hemophilia A gene therapy program could still be influencing investor sentiment. On December 30, 2024, Sangamo announced it would regain full rights to the program after Pfizer decided to cease its development. This has led to speculation about Sangamo's next steps, such as finding a new partner or advancing the program independently. Despite this potential opportunity, the lack of immediate positive developments may be contributing to the stock's current performance.
Sangamo Therapeutics, Inc. (SGMO) is trading at $1.20, down 1.23% from the previous close of $1.22. The stock opened at $1.24 and has fluctuated between a high of $1.25 and a low of $1.19. With a volume of 705,825 shares, representing only 6.79% of its average daily volume of 10,394,418, trading activity is relatively low, which is typical for this early in the trading day.